Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates.
Accelerating the transition to late-stage clinical production and commercialization
This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch.
'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom.
Exosomes at the heart of the development of promising new biotherapies
Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells.
EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability).
EVerGel, EVerZom's first drug candidate for Crohn's disease
EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group.
Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030.
High potential far beyond the targeted indications
Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics.
Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@fp2com.fr
About EVerZom
Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology.
About France 2030
✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization.
✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle).
✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support.
✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires.
More information: france2030.gouv.fr | @SGPI_avenir
About the 'Innovations in Biotherapies and Bioproduction' call for projects
The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside.
About Bpifrance
Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges.
More information: www.bpifrance.fr - https://presse.bpifrance.fr/ - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn
Attachment
Everzom_PR_Winner_France_2030_VDEF
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Castine Unveils Transformative RMS Upgrade, Redefining Research Management for Asset Managers
Incorporates 100 million New Data Elements to Revolutionize Financial Intelligence Access RIDGEWOOD, N.J., July 24, 2025--(BUSINESS WIRE)--Castine unveiled a major upgrade to its Research Management System, introducing reimagined functionality and the addition of over 100 million financial instrument data elements to its library. The current RMS system is used globally by asset managers to organize, tag, and extract value from both internally generated research as well as content received from hundreds of brokers and research providers. The system became part of Castine's offering following its recent acquisition of Paris-based ResearchPool. The RMS enhancements include an expanded central repository with full integration into Microsoft Office, enabling users to tag and catalog documents at the point of creation, significantly boosting the efficiency and accuracy of repository-wide searches. Personalized Intelligence at Scale Perhaps most revolutionary is the RMS's ability to reflect each user's unique research methodology, business rules and relationship network. Instead of requiring professionals to conform to rigid software structures, the RMS now adapts to their individual workflows, serving as a digital extension of their analytical process. The platform's newly introduced fund holdings views and interactive corporate hierarchy diagrams deliver unprecedented transparency into complex financial structures. Users can now seamlessly visualize end-to-end parent-subsidiary connections with intuitive clarity that reshapes the investment decision-making process. "We're moved beyond simply managing research, we're creating a living, breathing ecosystem where every datapoint contributes to a broader intelligence network," said Robin Hodgkins, President of Castine Consulting LLC. "With these new capabilities, and our expanded data library, Castine RMS is now positioned as the 'command center' for next-generation research operations." The development and rollout of the upgraded RMS were a collaborative effort across teams in France, Portugal, and Argentina. "This has been a true team achievement, showcasing the strengths of our long-standing group and the expanded capabilities we now offer as part of the Castine family," said Castine Director Pedro Fernandes, former President of ResearchPool who led the design and architecture of the RMS suite. The enhanced platform will be available to clients beginning September 1st. About Castine Castine is a global leader in commission management and research solutions, with over 30 years of experience supporting CSA and research programs. Castine serves more than 500 asset managers and brokers and 2000+ research provider. Offices in the United Kingdom, Europe, Argentina, and the United States. View source version on Contacts Robin HodgkinsPresident, Castine LLCrh@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Castine Unveils Transformative RMS Upgrade, Redefining Research Management for Asset Managers
RIDGEWOOD, N.J.--(BUSINESS WIRE)--Castine unveiled a major upgrade to its Research Management System, introducing reimagined functionality and the addition of over 100 million financial instrument data elements to its library. 'We're creating a living, breathing ecosystem where every datapoint contributes to a broader intelligence network,' said Robin Hodgkins Share The current RMS system is used globally by asset managers to organize, tag, and extract value from both internally generated research as well as content received from hundreds of brokers and research providers. The system became part of Castine's offering following its recent acquisition of Paris-based ResearchPool. The RMS enhancements include an expanded central repository with full integration into Microsoft Office, enabling users to tag and catalog documents at the point of creation, significantly boosting the efficiency and accuracy of repository-wide searches. Personalized Intelligence at Scale Perhaps most revolutionary is the RMS's ability to reflect each user's unique research methodology, business rules and relationship network. Instead of requiring professionals to conform to rigid software structures, the RMS now adapts to their individual workflows, serving as a digital extension of their analytical process. The platform's newly introduced fund holdings views and interactive corporate hierarchy diagrams deliver unprecedented transparency into complex financial structures. Users can now seamlessly visualize end-to-end parent-subsidiary connections with intuitive clarity that reshapes the investment decision-making process. 'We're moved beyond simply managing research, we're creating a living, breathing ecosystem where every datapoint contributes to a broader intelligence network,' said Robin Hodgkins, President of Castine Consulting LLC. 'With these new capabilities, and our expanded data library, Castine RMS is now positioned as the 'command center' for next-generation research operations.' The development and rollout of the upgraded RMS were a collaborative effort across teams in France, Portugal, and Argentina. 'This has been a true team achievement, showcasing the strengths of our long-standing group and the expanded capabilities we now offer as part of the Castine family,' said Castine Director Pedro Fernandes, former President of ResearchPool who led the design and architecture of the RMS suite. The enhanced platform will be available to clients beginning September 1st. About Castine Castine is a global leader in commission management and research solutions, with over 30 years of experience supporting CSA and research programs. Castine serves more than 500 asset managers and brokers and 2000+ research provider. Offices in the United Kingdom, Europe, Argentina, and the United States.
The Hill
3 hours ago
- The Hill
8 children suffered seizure-like symptoms at youth choir concert
(NewsNation) — Massachusetts officials took eight children to hospitals after displaying seizure-like symptoms during a youth choir performance at a church near Harvard University on Tuesday. The symptoms weren't life-threatening for the 'pre-teen' and 'early teen youths' impacted, and dozens of other attendees were not affected, according to the fire department for the city of Cambridge, Mass. The cause is still unknown, but officials said initial air testing found that 'no hazardous conditions were present' at St. Paul's Parish in Harvard Square. Man indicted for allegedly planting homemade IEDs in Manhattan Nearly 80 people gathered at the church Tuesday for a free performance by French youth choir, the Chœur d'Enfants d'Île-de-France. St. Paul announced the event days prior in a Facebook post: 'Founded in 1970, the youth choir has travelled extensively and performed with some of the world's top conductors and soloists. The concert will feature and exciting mix of sacred and secular repertoire, as well as popular French songs.' Local reporting indicated that the affected children were part of the choir, though officials have not confirmed that publicly. Seizure symptoms can include confusion, jerking movements of extremities, losing consciousness or sharp changes in emotions or thinking, according to the Mayo Clinic. They're caused by a disruption between nerve cells in the brain, which can be triggered by epilepsy, illness, injuries or other factors.
